Company Overview and News

 
Chinese developer Future Land’s US$650 million privatisation bid rejected by shareholders

2017-10-17 scmp
Billionaire Wang Zhenhua’s plan to take his Hong Kong-listed Future Land Development private failed after shareholders rejected the HK$3.30 per share cash bid

 
Future Land shares soar to near record in Hong Kong on founder’s plan to take developer private

2017-07-19 scmp
Shares of Future Land Development jumped almost 14 per cent to an 11-day intraday high in Hong Kong, after the developer unveiled plans to take its business private.

 
Chinese developer Future Land looks set for privatisation

2017-07-10 scmp
Future Land Development, a Chinese property developer listed in Hong Kong, requested a trading halt on Monday pending an announcement related to a possible privatisation of the company.

 
UPDATE 4-Smaller cities keep China home property market hot in April

2017-05-18 reuters
BEIJING Home prices in Beijing and some major Chinese cities softened in April due to ongoing curbs to cool China's red-hot property market, but average prices nationwide saw their largest increase in six months, helped by purchases in smaller cities.

 
Main Securities Market Notice

2016-12-07 londonstockexchange
The board of the Irish Stock Exchange approves the admission of the undermentioned securities to listing on the Official List and trading on the Main Securities Market of the ISE.

 
D-BOX Technologies follows up the success of their first all D-BOX theatre in China with two more venues

2016-12-05 marketwired
LONGUEUIL, QUÉBEC--(Marketwired - Dec. 5, 2016) - D-BOX Technologies Inc. ("D-BOX") (TSX:DBO), a world leader in immersive motion cinema seating technology, is excited to announce they will install D-BOX high-fidelity motion systems into two more full-size auditoriums in China.

 
What bubble? Experts say extreme distortions in supply-demand are driving up home prices in Beijing and Shanghai

2016-11-01 scmp
New land supply in the capital is equivalent 12,200 units, compared with 95,000 sold so far this year

 
D-BOX Technologies To Launch the First All D-BOX Theater in China with Shanghai Bestar Cinemas Management Co., Ltd

2016-09-21 marketwired
LONGUEUIL, QUÉBEC--(Marketwired - Sept. 20, 2016) - D-BOX Technologies Inc. (D-BOX) (TSX:DBO), a pioneer and world leader in immersive cinematic D-BOX Motion Code®, will install a full-size auditorium with D-BOX high-fidelity motion systems with Shanghai Bestar Cinemas Management Co., Ltd. The theater situated in Haikou, in the province of Haïnan, will be branded as Bestar D-BOX Cinema and will be able to seat 143 moviegoers and will be the first venue in China to offer an entire audience the full D-BOX experience.

 
IMAX Signs 10-Theatre Agreement with Shanghai Bestar Cinemas Management Co. Ltd. in China

2016-05-03 prnewswire
Top Chinese Property Developer Future Land Holdings Launches Exhibition Business; IMAX to Serve as Anchor Attraction for Shanghai Bestar Cinemas Management Co. Ltd.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...